Trial Profile
A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chipscreen Biosciences
- 28 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jul 2015 Planned End Date changed from 1 Oct 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.